REFERENCES

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, et al. Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87-108.

2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.

3. Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology 2016;150:835-53.

4. Colli A, Fraquelli M, Casazza G, Massironi S, Colucci A, et al. Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. Am J Gastroenterol 2006;101:513-23.

5. Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology 2016;150:835-53.

6. Tsuchiya N, Sawada Y, Endo I, Saito K, Uemura Y, et al. Biomarkers for the early diagnosis of hepatocellular carcinoma. World J Gastroenterol 2015;21:10573-83.

7. Mizejewski GJ. Alpha-fetoprotein structure and function: relevance to isoforms, epitopes, and conformational variants. Exp Biol Med 2001;226:377-408.

8. Gitlin D, Perricelli A, Gitlin JD. The presence of serum alphafetoprotein in sharks and its synthesis by fetal gastrointestinal tract and liver. Comp BiochemPhysiol B 1973;46:207-15.

9. Debruyne EN, Delanghe JR. Diagnosing and monitoring hepatocellular carcinoma with alpha-fetoprotein: new aspects and applications. Clin Chim Acta 2008;395:19-26.

10. Chayvialle JA, Ganguli PC. Radioimmunoassay of alpha-fetoprotein in human plasma. Lancet 1973;1:1355-7.

11. Waldmann TA, McIntire KR. The use of a radioimmunoassay for alpha-fetoprotein in the diagnosis of malignancy. Cancer 1974;34:1510-5.

12. Chayvialle JA, Ganguli PC. Radioimmunoassay of alpha-fetoprotein in human plasma. Lancet 1973;1:1355-7.

13. Lederle FA, Pocha C. Screening for liver cancer: the rush to judgment. Ann Intern Med 2012;156:387-9.

14. Chen JG, Parkin DM, Chen QG, Lu JH, Shen QJ, et al. Screening for liver cancer: results of a randomized controlled trial in Qidong, China. J Med Screen 2003;10:204-9.

15. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004;130:417-22.

16. Muguti G, Tait N, Richardson A, Little JM. Alpha-fetoprotein expression in hepatocellular carcinoma: a clinical study. J Gastroenterol Hepatol 1992;7:374-8.

17. Chu CW, Hwang SJ, Luo JC, Lai CR, Tsay SH, et al. Clinical, virologic, and pathologic significance of elevated serum alpha-fetoprotein levels in patients with chronic hepatitis C. J Clin Gastroenterol 2001;32:240-4.

18. Talerman A, Haije WG, Baggerman L. Serum alphafetoprotein (AFP) in patients with germ cell tumors of the gonads and extragonadal sites: correlation between endodermal sinus (yolk sac) tumor and raised serum AFP. Cancer 1980;46:380-5.

19. Ucar E, Semerci E, Ustun H, Yetim T, Huzmeli C, et al. Prognostic value of preoperative CEA, CA 19-9, CA 72-4, and AFP levels in gastric cancer. Adv Ther 2008;25:1075-84.

20. Li D, Mallory T, Satomura S. AFP-L3: a new generation of tumor marker for hepatocellular carcinoma. Clin Chim Acta 2001;313:15-9.

21. Sterling RK, Jeffers L, Gordon F, Venook AP, Reddy KR, et al. Utility of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gammacarboxy prothrombin, alone or in combination, as biomarkers for hepatocellular carcinoma. Clin Gastroenterol Hepatol 2009;7:104-13.

22. Marrero JA, Feng Z, Wang Y, Nguyen MH, Befeler AS, et al. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectinbound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology 2009;137:110-8.

23. Kagebayashi C, Yamaguchi I, Akinaga A, Kitano H, Yokoyama K, et al. Automated immunoassay system for AFP-L3% using on-chip electrokinetic reaction and separation by affinity electrophoresis. Anal Biochem 2009;388:306-11.

24. Reichl P, Fang M, Starlinger P, Staufer K, Nenutil R, et al. Multicenter analysis of soluble Axl reveals diagnostic value for very early stage hepatocellular carcinoma. Int J Cancer 2015;137:385-94.

25. Zhang Z, Lee JC, Lin L, Olivas V, Au V, et al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet 2012;44:852-60.

26. Rankin EB, Fuh KC, Taylor TE, Krieg AJ, Musser M, et al. AXL is an essential factor and therapeutic target for metastatic ovarian cancer. Cancer Res 2010;70:7570-9.

27. Dunne PD, McArt DG, Blayney JK, Kalimutho M, Greer S, et al. AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancer. Clin Cancer Res 2014;20:164-75.

28. D’Alfonso TM, Hannah J, Chen Z, Liu Y, Zhou P, et al. Axl receptor tyrosine kinase expression in breast cancer. J Clin Pathol 2014;67:690-6.

29. Song X, Wang H, Logsdon CD, Rashid A, Fleming JB, et al. Overexpression of receptor tyrosine kinase Axl promotes tumor cell invasion and survival in pancreatic ductal adenocarcinoma. Cancer 2011;117:734-43.

30. Varnum BC, Young C, Elliott G, Garcia A, Bartley TD, et al. Axl receptor tyrosine kinase stimulated by the vitamin K-dependent protein encoded by growth-arrest-specific gene 6. Nature 1995;373:623-6.

31. Fridell YW, Jin Y, Quilliam LA, Burchert A, McCloskey P, et al. Differential activation of the Ras/extracellularsignal-regulated protein kinase pathway is responsible for the biological consequences induced by the Axl receptor tyrosine kinase. Mol Cell Biol 1996;16:135-45.

32. Tai KY, Shieh YS, Lee CS, Shiah SG, Wu CW. Axl promotes cell invasion by inducing MMP-9 activity through activation of NF-kappaB and Brg-1. Oncogene 2008;27:4044-55.

33. Ruan GX, Kazlauskas A. Axl is essential for VEGF-A-dependent activation of PI3K/Akt. EMBO J 2012;31:1692-703.

34. Paccez JD, Vasques GJ, Correa RG, Vasconcellos JF, Duncan K, et al. The receptor tyrosine kinase Axl is an essential regulator of prostate cancer proliferation and tumor growth and represents a new therapeutic target. Oncogene 2013;32:689-98.

35. Hong CC1, Lay JD, Huang JS, Cheng AL, Tang JL, et al. Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia. Cancer Lett 2008;268:314-24.

36. Neubauer A, Fiebeler A, Graham DK, O’Bryan JP, Schmidt CA, et al. Expression of axl, a transforming receptor tyrosine kinase, in normal and malignant hematopoiesis. Blood 1994;84:1931-41.

37. Shieh YS, Lai CY, Kao YR, Shiah SG, Chu YW, et al. Expression of axl in lung adenocarcinoma and correlation with tumor progression. Neoplasia 2005;7:1058-64.

38. Li N, Liu Z, Zhang Y, Chen Q, Liu P, et al. Mice lacking Axl and Mer tyrosine kinase receptors are susceptible to experimental autoimmune orchitis induction. Immunol Cell Biol 2015;93:311-20.

39. Weinger JG, Brosnan CF, Loudig O, Goldberg MF, Macian F, et al. Loss of the receptor tyrosine kinase Axl leads to enhanced inflammation in the CNS and delayed removal of myelin debris during experimental autoimmune encephalomyelitis. J Neuroinflammation 2011;8:49.

40. Xu MZ, Chan SW, Liu AM, Wong KF, Fan ST, et al. AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma. Oncogene 2011;30:1229-40.

41. Gay CM, Balaji K, Byers LA. Giving AXL the axe: targeting AXL in human malignancy. Br J Cancer 2017;116:415-23.

42. Pinato DJ, Mauri FA, Lloyd T, Vaira V, Casadio C, et al. The expression of Axl receptor tyrosine kinase influences the tumour phenotype and clinical outcome of patients with malignant pleural mesothelioma. Br J Cancer 2013;108:621-8.

43. Reichl P, Fang M, Starlinger P, Staufer K, Nenutil R, et al. Multicenter analysis of soluble Axl reveals diagnostic value for very early stage hepatocellular carcinoma. Int J Cancer 2015;137:385-94.

44. Nordberg J, Arnér ES. Reactive oxygen species, antioxidants, and the mammalian thioredoxin system. Free Radic Biol Med 2001;31:1287-312.

45. Kakolyris S, Giatromanolaki A, Koukourakis M, Powis G, Souglakos J, et al. Thioredoxin expression is associated with lymph node status and prognosis in early operable non-small cell lung cancer. Clin Cancer Res 2001;7:3087-91.

46. Raffel J, Bhattacharyya AK, Gallegos A, Cui H, Einspahr JG, et al. Increased expression of thioredoxin-1 in human colorectal cancer is associated with decreased patient survival. J Lab Clin Med 2003;142:46-51.

47. Li J, Cheng ZJ, Liu Y, Yan ZL, Wang K, et al. Serum thioredoxin is a diagnostic marker for hepatocellular carcinoma. Oncotarget 2015;6:9551-63.

48. Yang J, Li J, Dai W, Wang F, Shen M, et al. Golgi protein 73 as a biomarker for hepatocellular carcinoma: a diagnostic meta-analysis. Exp Ther Med 2015;9:1413-20.

49. Jin D, Tao J, Li D, Wang Y, Li L, et al. Golgi protein 73 activation of MMP-13 promotes hepatocellular carcinoma cell invasion. Oncotarget 2015;6:33523-33.

50. Bachert C, Fimmel C, Linstedt AD. Endosomal trafficking and proprotein convertase cleavage of cis Golgi Protein GP73 produces marker for hepatocellular carcinoma. Traffic 2007;8:1415-24.

51. Kladney RD, Cui X, Bulla GA, Brunt EM, Fimmel CJ. Expression of GP73, a resident Golgi membrane protein, in viral and nonviral liver disease. Hepatology 2002;35:1431-40.

52. Mao Y, Yang H, Xu H, Lu X, Sang X, et al. Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma. Gut 2010;59:1687-93.

53. El-Abd N, Fawzy A, Elbaz T, Hamdy S. Evaluation of annexin A2 and as potential biomarkers for hepatocellular carcinoma. Tumor Biol 2016;37:211-6.

54. Attallah AM, El-Far M, Malak CA, Omran MM, Shiha GE, et al. HCC-DETECT: a combination of nuclear, cytoplasmic, and oncofetal proteins as biomarkers for hepatocellular carcinoma. Tumor Biol 2015;36:7667-74.

55. Attallah AM, El-Far M, Abdel Malak CA, Farid K, Omran MM, et al. A simple diagnostic index comprising epithelial membrane antigen and fibronectin for hepatocellular carcinoma. Ann Hepatol 2015;14:869-80.

56. Mao L, Wang Y, Wang D, Han G, Fu S, et al. TEMs but not DKK1 could serve as complementary biomarkers for AFP in diagnosing AFP-negative hepatocellular carcinoma. PLoS One 2017;12:e0183880.

57. Filmus J. The contribution of in vivo manipulation of gene expression to the understanding of the function of glypicans. Glycoconj J 2002;19:319-23.

58. Veugelers M, De Cat B, Ceulemans H, Bruystens AM, Coomans C, et al. Glypican-6, a new member of the glypican family of cell surface proteoglycans. J Biol Chem 1999;274:26968-77.

59. Traister A, Shi W, Filmus J. Mammalian Notum induces the release of glypicans and other GPI anchored proteins from the cell surface. Biochem J 2008;410:503-11.

60. Nakatsura T1, Kageshita T, Ito S, Wakamatsu K, Monji M, et al. Identification of glypican-3 as a novel tumor marker for melanoma. Clin Cancer Res 2004;10:6612-21.

61. Hsu HC, Cheng W, Lai PL. Cloning and expression of a developmentally regulated transcript MXR7 in hepatocellular carcinoma: biological significance and temporospatial distribution. Cancer Res 1997;57:5179-84.

62. Zhu ZW, Friess H, Wang L, Abou-Shady M, Zimmermann A, et al. Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders. Gut 2001;48:558-64.

63. Nakatsura T, Yoshitake Y, Senju S, Monji M, Komori H, et al. Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem Biophys Res Commun 2003;306:16-25.

64. Hippo Y, Watanabe K, Watanabe A, Midorikawa Y, Yamamoto S, et al. Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma. Cancer Res 2004;64:2418-23.

65. Capurro MI, Xiang YY, Lobe C, Filmus J. Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. Cancer Res 2005;65:6245-54.

66. Filmus J, Capurro M, Rast J. Glypicans. Genome Biol 2008;9:224.

67. Filmus J, Capurro M. The role of glypican-3 in the regulation of body size and cancer. Cell Cycle 2008;7:2787-90.

68. Feitelson MA, Sun B, Tufan NLS, Liu J, Pan J, et al. Genetic mechanisms of hepatocarcinogenesis. Oncogene 2002;21:2593-604.

69. Kern MA, Breuhahn K, Schirmacher P. Molecular pathogenesis of human hepatocellular carcinoma. Adv Cancer Res 2002;67:112.

70. Xiang YY, Ladeda V, Filmus J. Glypican-3 expression is silenced in human breast cancer. Oncogene 2001;20:7408-12.

71. Lin H, Huber R, Schlessinger D, Morin PJ. Frequent silencing of the GPC3 gene in ovarian cancer cell lines. Cancer Res 1999;59:807-10.

72. Kim H, Xu GL, Borczuk AC, Busch S, Filmus J, et al. The heparan sulfate proteoglycan GPC3 is a potential lung tumor suppressor. Am J Resp Cell Mol Biol 2003;29:694-701.

73. Capurro MI, Xu P, Shi W, Li F, Jia A, et al. Glypican-3 inhibits hedgehog signaling during development by competing with Patched for Hedgehog binding. Dev Cell 2008;14:700-11.

74. Tangkijvanich P, Chanmee T, Komtong S, Mahachai V, Wisedopas N, et al. Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers. J Gastroenterol Hepatol 2010;25:129-37.

75. Jia X, Liu J, Gao Y, Huang Y, Du Z. Diagnosis accuracy of serum glypican-3 in patients with hepatocellular carcinoma: a systematic review with meta-analysis. Arch Med Res 2014;45:580-8.

76. Nakatsura T, Komori H, Kubo T, Yoshitake Y, Senju S, et al. Mouse homologue of a novel human oncofetal antigen, glypican-3, evokes T-cell-mediated tumor rejection without autoimmune reactions in mice. Clin Cancer Res 2004;10:8630-40.

77. Motomura Y, Senju S, Nakatsura T, Matsuyoshi H, Hirata S, et al. Embryonic stem cell-derived dendritic cells expressing glypican-3, a recently identified oncofetal antigen, induce protective immunity against highly metastatic mouse melanoma, B16-F10. Cancer Res 2006;66:2414-22.

78. Sawada Y, Yoshikawa T, Nobuoka D, Shirakawa H, Kuronuma T, et al. Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival. Clin Cancer Res 2012;18:3686-96.

79. Gao H, Li K, Tu H, Pan X, Jiang H, et al. Development of T Cells Redirected to Glypican-3 for the Treatment of Hepatocellular Carcinoma. Clin Cancer Res 2014;20:6418.

80. Zhai B, Shi D, Gao H, Qi X, Jiang H, et al. A phase I study of anti-GPC3 chimeric antigen receptor modified T cells (GPC3 CAR-T) in Chinese patients with refractory or relapsed GPC3+ hepatocellular carcinoma (r/r GPC3+ HCC). J Clin Oncol 2017;35:3049.

81. Ishiguro T, Sano Y, Komatsu SI, Kamata-Sakurai M, Kaneko A, et al. An anti-glypican 3/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors. Sci Transl Med 2017;9:eaal4291.

82. Gessner R, Tauber R. Intestinal cell adhesion molecules. Liver-intestine cadherin. Ann N Y Acad Sci 2000;915:136-43.

83. Berndorff D, Gessner R, Kreft B, Schnoy N, Lajous-Petter AM, et al. Liver-intestine cadherin: molecular cloning and characterization of a novel Ca2+-dependent cell adhesion molecule expressed in liver and intestine. J Cell Biol 1994;125:1353-69.

84. Dantzig AH, Hoskins JA, Tabas LB, Bright S, Shepard RL, et al. Association of intestinal peptide transport with a protein related to the cadherin superfamily. Science 1994;264:430-3.

85. Wong BW, Luk JM, Ng IO, Hu MY, Liu KD, et al. Identification of liver-intestine cadherin in hepatocellular carcinoma--a potential disease marker. Biochem Biophys Res Commun 2003;311:618-24.

86. Grotzinger C, Kneifel J, Patschan D, Schnoy N, Anagnostopoulos I, et al. LI-cadherin: a marker of gastric metaplasia and neoplasia. Gut 2001;49:73-81.

87. Takamura M, Sakamoto M, Ino Y, Shimamura T, Ichida T, et al. Expression of liverintestine cadherin and its possible interaction with galectin-3 in ductal adenocarcinoma of the pancreas. Cancer Sci 2003;94:425-30.

88. Wang XQ, Luk JM, Leung PP, Wong BW, Stanbridge EJ, et al. Alternative mRNA splicing of liver intestine-cadherin in hepatocellular carcinoma. Clin Cancer Res 2005;11:483-9.

89. Takamura M, Ichida T, Matsuda Y, Kobayashi M, Yamagiwa S, et al. Reduced expression of liver-intestine cadherin is associated with progression and lymph node metastasis of human colorectal carcinoma. Cancer Lett 2004;212:253-9.

90. Wong BW, Luk JM, Ng IO, Hu MY, Liu KD, et al. Identification of liver intestine cadherin in hepatocellular carcinoma - a potential disease marker. Biochem Biophys Res Commun 2003;311:618-24.

91. Hinoi T, Lucas PC, Kuick R, Hanash S, Cho KR, et al. CDX2 regulates liver intestine-cadherin expression in normal and malignant colon epithelium and intestinal metaplasia. Gastroenterology 2002;123:1565-77.

92. Park JH, Seol JA, Choi HJ, Roh YH, Choi PJ, et al. Comparison of cadherin-17 expression between primary colorectal adenocarcinomas and their corresponding metastases: the possibility of a diagnostic marker for detecting the primary site of metastatic tumour. Histopathology 2011;58:315-8.

93. Bartolome RA, Barderas R, Torres S, Fernandez-Acenero MJ, Mendes M, et al. Cadherin-17 interacts with a2b1 integrin to regulate cell proliferation and adhesion in colorectal cancer cells causing liver metastasis. Oncogene 2014;33:1658-69.

94. Liu LX, Lee NP, Chan VW, Xue W, Zender L, et al. Targeting cadherin-17 inactivates Wnt signaling and inhibits tumor growth in liver carcinoma. Hepatology 2009;50:1453-63.

95. Su MC, Yuan RH, Lin CY, Jeng YM. Cadherin-17 is a useful diagnostic marker for adenocarcinomas of the digestive system. Mod Pathol 2008;21:1379-86.

96. Okada T, Kurabayashi A, Akimitsu N, Furihata M. Expression of cadherin-17 promotes metastasis in a highly bone marrow metastatic murine breast cancer model. Biomed Res Int 2017;2017:8494286.

97. Bartolomé RA, Aizpurua C, Jaén M, Torres S, Calviño E, et al. Monoclonal antibodies directed against cadherin RGD exhibit therapeutic activity against melanoma and colorectal cancer metastasis. Clin Cancer Res 2018;24:433-44.

98. Zender L, Spector MS, Xue W, Flemming P, Cordon-Cardo C, et al. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell 2006;125:1253-67.

99. Overholtzer M, Zhang J, Smolen GA, Muir B, Li W, et al. Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc Natl Acad Sci USA 2006;103:12405-10.

100. Morin-Kensicki EM, Boone BN, Howell M, Stonebraker JR, Teed J, et al. Defects in yolk sac vasculogenesis, chorioallantoic fusion, and embryonic axis elongation in mice with targeted disruption of Yap65. Mol Cell Biol 2006;26:77-87.

101. Zhao B, Ye X, Yu J, Li L, Li W, et al. TEAD mediates YAP-dependent gene induction and growth control. Genes Dev 2008;22:1962-71.

102. Dong J, Feldmann G, Huang J, Wu S, Zhang N, et al. Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell 2007;130:1120-33.

103. Wu H, Liu Y, Jiang XW, Li WF, Guo G, et al. Clinicopathological and prognostic significance of Yes-associated protein expression in hepatocellular carcinoma and hepatic cholangiocarcinoma. Tumour Biol 2016;37:13499-508.

104. Xu MZ, Yao TJ, Lee NP, Ng IO, Chan YT, et al. Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer 2009;115:4576-85.

105. Wang Y, Dong Q, Zhang Q, Li Z, Wang E, et al. Overexpression of yes-associated protein contributes to progression and poor prognosis of non-small-cell lung cancer. Cancer Sci 2010;101:1279-85.

106. Hayashi H, Higashi T, Yokoyama N, Kaida T, Sakamoto K, et al. An imbalance in TAZ and YAP expression in hepatocellular carcinoma confers cancer stem cell-like behaviors contributing to disease progression. Cancer Res 2015;75:4985-97.

107. Lamar JM, Stern P, Liu H, Schindler JW, Jiang ZG, et al. The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain. Proc Natl Acad Sci U S A 2012;109:E2441-50.

108. Zhou Z, Hu T, Xu Z, Lin Z, Zhang Z, et al. Targeting Hippo pathway by specific interruption of YAP-TEAD interaction using cyclic YAP-like peptides. FASEB J 2015;29:724-32.

109. Gibault F, Coevoet M, Sturbaut M, Farce A, Renault N, et al. Toward the discovery of a novel class of YAP-TEAD interaction inhibitors by virtual screening approach targeting YAP-TEAD protein-protein interface. Cancers (Basel) 2018;10:E140.

110. Guerra E, Trerotola M, Aloisi AL, Tripaldi R, Vacca G, et al. The Trop-2 signalling network in cancer growth. Oncogene 2013;32:1594-600.

111. Fong D, Moser P, Krammel C, Gostner JM, Margreiter R, et al. High expression of TROP2 correlates with poor prognosis in pancreatic cancer. Br J Cancer 2008;99:1290-5.

112. Fong D, Spizzo G, Gostner JM, Gastl G, Moser P, et al. TROP2: a novel prognostic marker in squamous cell carcinoma of the oral cavity. Mod Pathol 2008;21:186-91.

113. Mühlmann G, Spizzo G, Gostner J, Zitt M, Maier H, et al. TROP2 expression as prognostic marker for gastric carcinoma. J Clin Pathol 2009;62:152-8.

114. Ning S, Guo S, Xie J, Xu Y, Lu X, et al. TROP2 correlates with microvessel density and poor prognosis in hilar cholangiocarcinoma. J Gastrointest Surg 2013;17:360-8.

115. Ohmachi T, Tanaka F, Mimori K, Inoue H, Yanaga K, et al. Clinical significance of TROP2 expression in colorectal cancer. Clin Cancer Res 2006;12:3057-63.

116. Liu T, Liu Y, Bao X, Tian J, Liu Y, et al. Overexpression of TROP2 predicts poor prognosis of patients with cervical cancer and promotes the proliferation and invasion of cervical cancer cells by regulating ERK signaling pathway. PLoS One 2013;8:e75864.

117. Bignotti E, Todeschini P, Calza S, Falchetti M, Ravanini M, et al. Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients. Eur J Cancer 2010;46:944-53.

118. Chen MB, Wu HF, Zhan Y, Fu XL, Wang AK, et al. Prognostic value of TROP2 expression in patients with gallbladder cancer. Tumour Biol 2014;35:11565-9.

119. Lin H, Huang JF, Qiu JR, Zhang HL, Tang XJ, et al. Significantly upregulated TACSTD2 and Cyclin D1 correlate with poor prognosis of invasive ductal breast cancer. Exp Mol Pathol 2013;94:73-8.

120. Gui T, Dong X, Li R, Li Y, Wang Z. Identification of hepatocellular carcinoma-related genes with a machine learning and network analysis. J Comput Biol 2015;22:63-71.

121. Ikeda Y, Imai Y, Kumagai H, Nosaka T, Morikawa Y, et al. Vasorin, a transforming growth factor beta-binding protein expressed in vascular smooth muscle cells, modulates the arterial response to injury in vivo. Proc Natl Acad Sci USA 2004;101:10732-7.

122. Chen L, Yao JH, Zhang SH, Wang L, Song HD, et al. Slit-like 2, a novel zebrafish slit homologue that might involve in zebrafish central neural and vascular morphogenesis. Biochem Biophys Res Commun 2005;336:364-71.

123. Li S, Li H, Yang X, Wang W, Huang A, et al. Vasorin is a potential serum biomarker and drug target of hepatocarcinoma screened by subtractive-EMSA-SELEX to clinic patient serum. Oncotarget 2015;6:10045-59.

124. Cao DX, Li ZJ, Jiang XO, Lum YL, Khin E, et al. Osteopontin as potential biomarker and therapeutic target in gastric and liver cancers. World J Gastroenterol 2012;18:3923-30.

125. Kim J, Ki SS, Lee SD, Han CJ, Kim YC, et al. Elevated plasma osteopontin levels in patients with hepatocellular carcinoma. Am J Gastroenterol 2006;101:2051-9.

126. Shang S, Plymoth A, Ge S, Feng Z, Rosen HR, et al. Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology 2012;55:483-90.

127. Sun T, Tang Y, Sun D, Bu Q, Li P. Osteopontin versus alpha-fetoprotein as a diagnostic marker for hepatocellular carcinoma: a meta-analysis. Onco Targets Ther 2018;11:8925-35.

128. Fouad SA, Mohamed NA, Fawzy MW, Moustafa DA. Plasma osteopontin level in chronic liver disease and hepatocellular carcinoma. Hepat Mon 2015;15:e30753.

129. Sun T, Li P, Sun D, Bu Q, Li G. Prognostic value of osteopontin in patients with hepatocellular carcinoma: A systematic review and meta-analysis. Medicine (Baltimore) 2018;97:e12954.

130. Liu K, Duan J, Liu H, Yang X, Yang J, et al. Precancer antiviral treatment reduces microvascular invasion of early-stage Hepatitis B-related hepatocellular carcinoma. Sci Rep 2019;9:2220.

131. Sun BS1, Dong QZ, Ye QH, Sun HJ, Jia HL, et al. Lentiviral-mediated miRNA against osteopontin suppresses tumor growth and metastasis of human hepatocellular carcinoma. Hepatology 2008;48:1834-42.

132. Shojaei F, Scott N, Kang X, Lappin PB, Fitzgerald AA, et al. Osteopontin induces growth of metastatic tumors in a preclinical model of non-small lung cancer. J Exp Clin Cancer Res 2012;31:26.

133. Dai J, Li B, Shi J, Peng L, Zhang D, et al. A humanized anti-osteopontin antibody inhibits breast cancer growth and metastasis in vivo. Cancer Immunol Immunother 2010;59:355-66.

134. Lim WA, June CH. The principles of engineering immune cells to treat cancer. Cell 2017;168:724-40.

135. Kershaw MH, Westwood JA, Parker LL, Wang G, Eshhar Z, et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res 2006;12:6106-15.

136. Lamers CH, Sleijfer S, van Steenbergen S, van Elzakker P, van Krimpen B, et al. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Mol Ther 2013;21:904-12.

137. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 2010;18:843-51.

138. van den Berg JH, Gomez-Eerland R, van de Wiel B, Hulshoff L, van den Broek D, et al. Case report of a fatal serious adverse event upon administration of T cells transduced with a MART-1-specific T-cell receptor. Mol Ther 2015;23:1541-50.

139. Gupta S, Bent S, Kohlwes J. Test characteristics of α-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C: A systematic review and critical analysis. Ann Intern Med 2003;139:46-50.

140. Shaheen KY, Abdel-Mageed AI, Safwat E, AlBreedy AM. The value of serum midkine level in diagnosis of hepatocellular carcinoma. Int J Hepatol 2015;2015:146389.

141. Giannelli G, Fransvea E, Trerotoli P, Beaugrand M, Marinosci F, et al. Clinical validation of combined serological biomarkers for improved hepatocellular carcinoma diagnosis in 961 patients. Clin Chim Acta 2007;383:147-52.

142. Sun Y, Gao G, Cai J, Wang Y, Qu X, et al. Annexin A2 is a discriminative serological candidate in early hepatocellular carcinoma. Carcinogenesis 2013;34:595-604.

143. Chounta A, Ellinas C, Tzanetakou V, Pliarhopoulou F, Mplani V, et al. Serum soluble urokinase plasminogen activator receptor as a screening test for the early diagnosis of hepatocellular carcinoma. Liver Int 2015;35:601-7.

Hepatoma Research
ISSN 2454-2520 (Online) 2394-5079 (Print)

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/